How is Thymosin Alpha-1 (Tα1) administered?
This describes how Thymosin Alpha-1 (Tα1) is typically administered in clinical and research references, not a self-administration guide. The usual route is Subcutaneous, on a 1-2x weekly schedule, generally over 4-8 weeks. Specific dosing is individual and beyond general information, and human evidence for Thymosin Alpha-1 (Tα1) is limited.
Administration at a glance (reference data)
- Route: Subcutaneous
- Schedule: 1-2x weekly
- Cycle length: 4-8 weeks
- Half-life: ~2 hours
References
- Thymosin alpha 1 in chronic hepatitis B and C — Sherman KE et al., Gut, 2003
- The efficacy and safety of thymosin alpha1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial — Wu J et al., BMJ, 2025
- The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial — Wu J et al., Critical Care, 2013
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Thymosin Alpha-1 (Tα1)
Full Thymosin Alpha-1 (Tα1) breakdownThymosin Alpha-1 (Tα1) what it's used forThymosin Alpha-1 (Tα1) side effectsThymosin Alpha-1 (Tα1) mistakes to avoidThymosin Alpha-1 (Tα1) who should avoid itThymosin Alpha-1 (Tα1) half-lifeThymosin Alpha-1 (Tα1) how long to workThymosin Alpha-1 (Tα1) legal statusThymosin Alpha-1 (Tα1) how it worksthymosin alpha 1 vs ll 37Ask the AI Coach
Last updated 2026-06-15.